PR
DFTX

PSP Research’s Definium Therapeutics DFTX Stock Holding History

PSP Research’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$470K Sell
10,000
-24,800
-71% -$613K 0.25% 24
2026
Q1 		$658K Sell
34,800
-41
-0.1% -$696 0.47% 4
2025
Q4 		$467K Buy
+34,841
New +$431K 0.41% 82

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PSP Research's DFTX Position: Q2 2026 in Review

PSP Research reduced its Definium Therapeutics (DFTX) stake by 71% in Q2 2026, selling an estimated $613K and leaving 10,000 shares worth $470K. The position accounts for 0.25% of the portfolio, ranked #24.

PSP Research first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $658K in Q1 2026. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • PSP Research held 10,000 shares of Definium Therapeutics worth $470K as of Q2 2026.
  • PSP Research sold 24,800 Definium Therapeutics shares in Q2 2026, an estimated $613K.
  • Definium Therapeutics made up 0.25% of PSP Research's portfolio in Q2 2026, its #24 holding.
  • PSP Research first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Definium Therapeutics position peaked at $658K in Q1 2026.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.